Jeffrey Kaufman
Pulmonary Disease · Columbus, OHNPI 1437157088
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. GSK accounts for 64.7% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $15,990 and has fallen 97.3% since, to $432 in 2021.
Across 150 payments — averaging $114.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- AstraZeneca$4K
- Viiv Healthcare Company$600
- Bayer$250
- Boehringer Ingelheim$162
- United Therapeutics Corporation$123
- plus $543 from 12 others
What the payments were for
- Consulting fees$3,35020%
- Speaking & faculty fees$8,20048%
- Travel & lodging$2,68916%
- Food & beverage$2,89917%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 62 | $11,103 |
| AstraZeneca | 33 | $4,384 |
| Viiv Healthcare Company | 1 | $600 |
| Bayer | 3 | $250 |
| Boehringer Ingelheim | 11 | $162 |
| United Therapeutics Corporation | 2 | $123 |
| Regeneron Healthcare Solutions, Inc. | 4 | $86 |
| Actelion Pharmaceuticals US, Inc. | 6 | $79 |
| Grifols USA, LLC | 5 | $69 |
| Philips North America LLC | 4 | $61 |
| Sunovion Pharmaceuticals Inc. | 5 | $61 |
| Sanofi | 3 | $55 |
| Novartis | 4 | $48 |
| Merck | 3 | $34 |
| Genentech USA, Inc. | 1 | $14 |
| Mylan Specialty L.p. | 1 | $12 |
| Pfizer | 1 | $12 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$9,624
- FASENRA$3,814
- Adempas$230
How this compares
$17,165 in reported general payments places this provider in the 85th percentile of 571 pulmonary disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 13 | $702 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Columbus
- Christian GhattasColumbus$286K
- Alberto ReveloColumbus$202K
- James FaganColumbus$179K
- Jeffrey HorowitzColumbus$31K
- Ehab HusseinColumbus$25K
- Joseph KhabbazaAkron$655K
- Robert BaughmanCincinnati$640K
- Kristin HighlandCleveland$551K
- Bruce CorserCincinnati$502K
- Jason StieneckerLima$397K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.